Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Second Genome raises $42.6mm through oversubscribed Series B round; SR One invests additional $8.4mm

Executive Summary

Pfizer Venture Investments and Roche Venture Fund co-led a $42.6mm Series B round for Second Genome Inc. (microbiome-based drug discovery for GI and metabolic diseases). The investors also take board seats. Additional participants in the oversubscribed round included new buyers Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, and the Mayo Clinic, along with Series A investors Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler, PhD.
Deal Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

UsernamePublicRestriction

Register